


This article was downloaded by: [Bowyer, Ben][informa internal users]

On: 6 February 2009

Access details: Access Details: [subscription number 755239602]

Publisher Informa Healthcare

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Gynecological Endocrinology

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title-content=t713395232>

Cimicifuga racemosa treatment and health related quality of life in post-menopausal Spanish women

Maria Dolores Juliá Mollá ^a; Yolanda García-Sánchez ^a; Alberto Romeu Sarrió ^a; Faustino R. Pérez-lópez ^b

^a Gynaecology and Reproduction Medicine Service, University Hospital La Fe, Valencia, Spain ^b Department of Obstetrics and Gynaecology, University of Zaragoza Hospital Clínico, Domingo Miral s/n, Zaragoza, Spain

Online Publication Date: 01 January 2009

To cite this Article Mollá, Maria Dolores Juliá, García-Sánchez, Yolanda, Sarrió, Alberto Romeu and Pérez-lópez, Faustino R. (2009) 'Cimicifuga racemosa treatment and health related quality of life in post-menopausal Spanish women', *Gynecological Endocrinology*, 25:1, 21 — 26

To link to this Article: DOI: 10.1080/09513590802404005

URL: <http://dx.doi.org/10.1080/09513590802404005>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

MENOPAUSE

Cimicifuga racemosa treatment and health related quality of life in post-menopausal Spanish women

MARIA DOLORES JULIÁ MOLLÁ¹, YOLANDA GARCÍA-SÁNCHEZ¹,
ALBERTO ROMEU SARRIÓ¹, & FAUSTINO R. PÉREZ-LÓPEZ²

¹Gynaecology and Reproduction Medicine Service, University Hospital La Fe, Valencia, Spain and ²Department of Obstetrics and Gynaecology, University of Zaragoza Hospital Clínico, Domingo Miral s/n, Zaragoza 50009, Spain

(Received 18 March 2008; accepted 12 August 2008)

Abstract

Objective. The effect of *Cimicifuga racemosa* (CR) treatment was evaluated in healthy symptomatic post-menopausal women using the Cervantes health-related quality of life (HR-QoL) scale.

Design. A prospective observational study was carried out in 122 healthy symptomatic post-menopausal Spanish women with elevated body weight, aged between 45 and 59 years. Three groups were formed according to age intervals. Each patient completed the Cervantes HR-QoL scale before and after CR treatment (20 mg, twice a day for 3 months). Changes in Cervantes scale global quality of life scores as well as in their domains (menopause and health, psychic, sexuality and couple relationship) were analysed.

Results. The CR treatment ameliorated global quality of life in both the whole group of patients and when women were analysed by age subgroups. There were significant positive changes in Z scores for the Cervantes HR-QoL scale 'menopause and health', and 'psychic' domains in both the entire population and by age groups. The 'sexuality domain' significantly improved when the entire population was assessed, but not when each age-group was separately analysed; while there were no changes in 'couple relationship domain' scores.

Conclusion. CR treatment increased both global quality of life and the four domains of the Cervantes HR-QoL scale, being an effective treatment to reduce symptoms in post-menopausal woman with elevated body weight.

Keywords: *Quality of life, Cervantes Quality of Life Scale, Cimicifuga racemosa, menopause, black cohosh, post-menopausal women, overweight, obesity*

Introduction

The menopause years are associated with symptoms and complaints that interfere with the biopsychosocial woman's life. Hormone therapy (HT), psychotropic drugs and botanical preparations have been proposed to treat menopause-related discomfort. Although the effectiveness of HT in alleviating symptoms is well proven, known side effects include withdrawal bleeds, breast tenderness, fluid retention, weight gain and headaches. Moreover, it may also carry its own increased risks, including breast and genital cancer, cardiovascular disease and thromboembolic disease [1–4]. The optimal treatment of climacteric symptoms would require efficacy and safety. Herbal therapeutics is gaining interest as an alternative to

hormones, since HT is no longer recommended as first-line therapy. The extract of *Cimicifuga racemosa* (CR), also known as *Actaea racemosa*, is popular as an alternative to HT in the treatment of menopausal symptoms such as hot flushes, mood disturbances, palpitations and vaginal dryness [5,6]. In experimental studies, CR has a mild positive effect on bone metabolism [7], and is devoid of biological activity on breast and uterus estrogenic receptors [8–10].

The concept of quality of life embraces numerous facets that include, aside from health, both a psychic as well as a sociological perspective with high subjective components. There are different scales or index to evaluate quality of life during the menopause transition, but few are specific to menopause [11–18]. All instruments seem to be reasonably structured and

have their place in applied research, although they are not available in different languages. Any evaluation should contemplate different aspects, including the physical, social and emotional domains, thereby allowing the evaluation of possible benefits or risks from different recommendations and therapies. Some quality of life scales only assess the climacteric aspects while the subjective and cultural components are not included, thus being of limited value. The Cervantes health-related quality of life (HR-QoL) scale is a simple, easy to apply, specific instrument for measuring quality of life during the menopause years, endorsed by the Spanish Menopause Society. It consists of 31 items that evaluate the quality of life in relation to health, symptoms of menopause and other aspects such as emotions, couple relationships and sexuality [13,18]. Menopausal status and body weight excess had a significant effect on women's quality of life, since post-menopausal women with elevated body mass index (BMI) have more limitations in social activity and less vitality than lean women [19,20]. Overweight and obese post-menopausal women have increased risk of heart disease, hypertension, diabetes, cancer, osteoarthritis and mental health problems. In addition, women with high BMI have an increased risk for moderate to severe hot flushes compared to women with low BMI [15,21]. Since the scarce information concerning the CR effects on quality of life in women with elevated BMI, this study assessed the effect produced by CR in symptomatic post-menopausal women as evaluated by the Cervantes HR-QoL scale.

Materials and methods

Healthy symptomatic Spanish post-menopausal women, aged between 45 and 59 years, with at least 12 months of amenorrhea and with mild to severe hot flushes were prospectively studied. The study was approved by the Institutional Board Review of the 'Hospital La Fe' in Valencia as an observational study of 150 patients, and women signed an informed consent form as a necessary requisite for their enrolment in the study. Patients were recruited from gynaecologic consultations if they have climacteric symptoms, would benefit from the use of CR treatment, and expressed their desire to take part in

the study. Patients were excluded if they had gynaecological surgery in the last 6 weeks, a history of hypersensitivity to CR, cardiac, renal or liver pathology, or any other serious illness. Women were not selected by any other criteria, and were representative of the general Spanish population, including their BMI values. General clinical characteristics are given in Table I. The final analysis included 122 patients who gave their informed consent, and completed the Cervantes HR-QoL scale, both before and after CR treatment. This scale is a 31-item, self-reporting questionnaire, including four categories or domains: 'Menopause and Health' with 15 items including vasomotor symptoms, health and ageing; 'Psychical Domain' with 9 items; 'Sexuality' with 4 items and 'Couple Relationship' with 3 items. Patients should rate each item between 0 and 5 using a Likert scale, and item responses are summed to create a global score and four different domain scores. Global and domain higher scores denote worse quality of life than lower values, and reduction of score values after an intervention indicates amelioration of the global or a domain quality of life. The Cervantes HR-QoL scale score can range from 0 to 155 points (from better to worse quality of life), and the scores can be compared with reference values in younger women and women of the same age (*Z* score). On the process of validation of the Cervantes scale, mean value for global score was 50.73 (SD 23.89), for menopause and health was 25.1 (SD 12.83), for menopause and psychical domain was 10.81 (SD 8.30), for sexuality was 10.54 (SD 5.00) and for couple relationship was 3.91 (SD 4.17) [13,18]. Values above +2 SD over the reference score in women of the same age and educational level were considered as 'severe symptoms', between +2 SD and +1 SD were considered as 'high-problem level', between +1 SD and -1 SD were considered as 'low-medium level' of HR-QoL and values below -1 SD were considered 'good level' of HR-QoL [13].

After treatment with 20 mg of CR (Remifemin[®], Schaper & Brümmer GMBH & Co. KG- Salzgitter Germany) twice a day orally for 3 months, subjects repeated the Cervantes scale questionnaire. Changes in the overall quality of life score and in the four domains of the questionnaire were analysed. The

Table I. Patient characteristics: mean \pm SD age, weight, height, body mass index, systolic and diastolic blood pressure.

	Age (M \pm SD)	Weight (M \pm SD)	Height (M \pm SD)	BMI (M \pm SD)	SBP (M \pm SD)	DBP (M \pm SD)
Total	52.3 \pm 4.5	69.9 \pm 11.6	1.6 \pm 0.6	28.2 \pm 4.7	127.2 \pm 19.1	78.0 \pm 11.2
45-49 years (<i>n</i> = 35)	48.3 \pm 1.6	68.1 \pm 12.6	1.6 \pm 0.1	26.9 \pm 4.4	121.0 \pm 16.4	76.2 \pm 11.4
50-54 years (<i>n</i> = 54)	51.5 \pm 1.4	68.7 \pm 12.1	1.6 \pm 0.5	27.5 \pm 4.8	123.8 \pm 18.2	78.4 \pm 11.3
55-59 years (<i>n</i> = 33)	56.6 \pm 1.5	69.2 \pm 10.7	1.6 \pm 0.6	28.3 \pm 4.3	128.3 \pm 20.2	78.6 \pm 11.1

There were no significant differences among age groups.

M, mean; SD, standard deviation; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.

analysis was carried out using the statistical program SPSS 11.0. The *t*-Student test was used for comparison of the quantitative variables, and the Chi-square test for qualitative variables. Statistical significance was considered for a $p < 0.05$.

Results

Patient demographic characteristics and relevant medical data are shown in Table I. They were representative of the general population, and as a group had an elevated mean BMI. The majority of patients belonged to the age group of 50–54 years. There were no significant differences among the variables when women were classified in three age groups, and CR treatment did not induce any significant change as compared with baseline values.

The mean scores (initial and after CR treatment) of the answers to the items of the Cervantes scale are shown in Table II. Overall quality of life scores significantly improved in women of all ages during CR treatment. There were significant positive changes in *Z* scores for the Cervantes HR-QoL scale ‘menopause and health’, and ‘psychic’ domains in both the entire population and in age groups. The ‘sexuality domain’ significantly improved when the entire population was assessed, but not when classified in three age

groups; while there were no changes in ‘couple relationship domain’ scores after CR treatment.

Discussion

Menopause is influenced by sociodemographic, psychosocial, culture and lifestyle factors [11–19]. Different studies have demonstrated that menopause supposes a deterioration in the quality of life [13,14,22]. Over the last years, it has become more frequent that studies incorporate this information as an instrument to assess the action of pharmacological, lifestyle or other interventions [23]. The assessment of menopause requires a variety of validated instruments to capture its influence in different populations, under different conditions and for a variety of outcomes. The Cervantes quality of life scale score creates a patient profile that can be used for clinical evaluation as well as when taking decisions. The instrument has been used in relation with the general population, for comparative purposes in obese and non-obese menopausal women, to study the metabolic syndrome, and to determine women’s perception of soy extract effects on climacteric-related symptoms [13,18,26,27]. In the present study, we used the Cervantes scale to evaluate healthy post-menopausal women with elevated body weight who complained to have hot flushes and received CR treatment.

Hot flushes often begin before menopause, tend to peak within 2–3 years after menopause, and lessen thereafter. But the range of patterns among menopausal women is quite diverse [28,29]. Previous results indicated that a higher percentage of body fat was associated with increased odds of reporting vasomotor symptoms in age- and site-adjusted models [15,21,29]. Recent studies suggest that hot flushes are triggered by small increases in the core body temperature, and that excess fat makes it more difficult for the body to dissipate heat.

In addition, obesity may be associated with hot flushes through mechanisms involving multiple hormones and sex hormone binding globulin [21]. Severe hot flushes are associated with chronic insomnia, increased blood pressure, mood disorders and decreased cognitive function that reduces quality of life [28–31]. In our present study, the whole population as well as age subgroups had elevated mean body weight values, and were representative of the Spanish general population [18,32]. Although Llana et al. [18] reported similar quality of life in post-menopausal women with elevated body weight, overweight and no-obese, other studies showed the opposite and firm conclusions are not possible since the lack of linear relationship between BMI and quality of life [15,19,33].

CR is indicated to treat menopause vasomotor and psychic symptoms due to its effects on the central

Table II. Mean scores (initial and after CR treatment) of the global and four domains of the Cervantes scale.

	Initial score (Mean ± SEM)	Final score (Mean ± SEM)
Cervantes scale global score		
Total (<i>n</i> = 122)	1.39 ± 0.08	0.64 ± 0.07*
45–49 years (<i>n</i> = 35)	1.46 ± 0.15	0.56 ± 0.15*
50–54 years (<i>n</i> = 54)	1.47 ± 0.11	0.75 ± 0.11*
55–59 years (<i>n</i> = 33)	1.25 ± 0.17	0.56 ± 0.13*
Menopause and health domain		
Total (<i>n</i> = 122)	1.58 ± 0.07	0.59 ± 0.07*
45–49 years (<i>n</i> = 35)	1.62 ± 0.13	0.53 ± 0.14*
50–54 years (<i>n</i> = 54)	1.57 ± 0.10	0.59 ± 0.11*
55–59 years (<i>n</i> = 33)	1.61 ± 0.15	0.63 ± 0.14*
Psychic domain		
Total (<i>n</i> = 122)	0.83 ± 0.08	0.37 ± 0.07*
45–49 years (<i>n</i> = 35)	0.97 ± 0.17	0.39 ± 0.16*
50–54 years (<i>n</i> = 54)	0.84 ± 0.11	0.40 ± 0.11*
55–59 years (<i>n</i> = 33)	0.79 ± 0.18	0.33 ± 0.16*
Sexuality domain		
Total (<i>n</i> = 122)	0.62 ± 0.08	0.49 ± 0.07**
45–49 years (<i>n</i> = 35)	0.59 ± 0.20	0.32 ± 0.16
50–54 years (<i>n</i> = 54)	0.81 ± 0.11	0.71 ± 0.11
55–59 years (<i>n</i> = 33)	0.38 ± 0.16	0.30 ± 0.13
Couple relationship domain		
Total (<i>n</i> = 122)	0.66 ± 0.08	0.60 ± 0.08
45–49 years (<i>n</i> = 35)	0.58 ± 0.17	0.42 ± 0.16
50–54 years (<i>n</i> = 54)	0.84 ± 0.14	0.84 ± 0.13
55–59 years (<i>n</i> = 33)	0.46 ± 0.15	0.36 ± 0.15

SEM, Standard error of the mean.

* $p < 0.001$ as compared to initial score.

** $p < 0.05$ as compared to initial score.

nervous system [5,6,33]. In the present study, CR treatment was associated with a significant improvement in global Cervantes HR-QoL score in post-menopausal women with elevated BMI. This intervention was not associated with changes in body weight. Quality of life improvements were quantified by global *Z* score reductions. We also found significant improvements in both the menopause and health domain and the psychic domain in both the whole studied population and in the three age groups. These results are concordant with those from Nappi et al. [34]. However, Osmer et al. [6] found a psychic improvement only in those patients with less than 3 years since the beginning of the symptoms, and the effectiveness of CR diminishes with years of menopause. A significant improvement in sexuality domain was associated to CR treatment in the entire population, but not in age groups probably due to the small number of cases; while there were no changes in the couple relationship domain scores. Since CR had no effects on vaginal epithelium, endometrium or reproductive hormones [35], our finding may be mainly related to a general neuronal effect of CR as a partial serotonin agonist at the receptor level [36], and to a dopaminergic action [6]. These mechanisms may explain the detected amelioration in both neurovegetative symptoms – such as flushes or sweats – and psychological symptoms – such as nervousness, irritability and sleep disorders – which affect the quality of life in post-menopausal women. Physical changes in quality of life as measured by the menopause and health domain, and on psycho-sexual aspects as measured by the psychic and sexuality domains, were improved in all age subgroups.

We are conscious of the limitations of a HR-QoL study and the difficulties involved in the interpretation of our data due to the problems associated with conducting and reporting subgroup analyses which can lead to overstated and misleading results. Other possible implications for data evaluation are the fact that samples were taken from gynaecological consultations and that women are a sample of urban, healthy, post-menopausal women. Considering these limitations, our data suggest that CR seems to be an acceptable option for the treatment of climacteric complaints which may deteriorate quality of life in post-menopausal women with elevated body weight. Although there are some controversial results, CR decreases climacteric complaints, has some antiproliferative effects, and is safe [6,7,9,34,35,37]. Its effectiveness has been evaluated in controlled as well as in uncontrolled trials. In a randomised, double blind study, the CR extract was as effective as equine conjugated estrogens in reducing menopausal symptoms, and also produces a reduction in anxiety and depression as determined with the Menopause Rating Scale [38]. In a prospective randomised study carried out in symptomatic menopausal women,

Nappi et al. [34] demonstrated that CR reduces the number of flushes and vasomotor symptoms at a similar level to that obtained with 25 µg/day of transdermal estradiol plus 10 mg/day of dihydrogestosterone, as evaluated with the Greene scale. In symptomatic menopausal women, Osmer et al. [6] demonstrated that the effectiveness of a 12-weeks CR treatment was greater as compared with placebo. The authors also evaluated four subscores (flushes, psyche, soma and atrophy), being the treatment most useful for flushes. In post-menopausal women treated with either fluoxetine or CR, the Kupperman Index decreased significantly under CR treatment as compared with the fluoxetine group by the end of the third month, whereas scores for hot flushes and night sweats significantly decreased in both groups [39]. However, CR reduced hot flushes and night sweats scores to a greater extent than did fluoxetine. The present study demonstrated that CR produced measurable benefits in climacteric complaints and quality of life in post-menopausal women with elevated body weight, which are considered as a high risk population to suffer hot flushes. The changes can be detected with the Cervantes HR-QoL scale. However, placebo effect cannot be ruled out by this treatment, moreover if observational design has been used.

Phytotherapy has been questioned due to a possible placebo effect [40]. The impact of placebo effect may be included in the assessment of symptoms and functional impairments or improvements where subjectivity, expectancy and motivation may significantly impact outcome evaluation. This phenomenon is also present in the conventional pharmacological interventions [41,42]. Nevertheless, it has been said that to induce a placebo effect to reduce discomfort associated to hot flushes might be helpful [43]. Thus, in some way the placebo effect is a part of the therapeutic effect. It is plausible that the strong affective component in high selected and motivated population, like in the present study, may have some bias. Further studies are needed to confirm the present results, and the effects of CR in longer duration treatment in post-menopausal women with the same cultural background. Prevention and early treatment of overweight and obesity are crucial to ensure health to post-menopausal women.

It can be concluded that the Cervantes scale allows the detection of changes in HR-QoL in post-menopausal women under CR treatment, and open a new avenue to use this instrument in other clinical interventions. Furthermore, quality of life was significantly improved by CR therapy system in post-menopausal women with elevated body weight. In all cases women's perception about their climacteric symptoms showed a significant improvement with CR treatment.

References

- Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet* 2003;362:419–427.
- Beral V, Million Women Study Collaborators, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. *Lancet* 2007;369:1703–1710.
- Canonico M, Plu-Bureau G, Lowe GDO, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. *BMJ* 2008;336:1227–1231.
- Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, et al. WHI Investigators Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. *JAMA* 2008;299:1036–1045.
- Winterhoff H, Spengler B, Christoffel V, Butterweck V, Löhning A. Cimicifuga extract BNO 1055: reduction of hot flushes and hints on antidepressant activity. *Maturitas* 2003; 44 (Suppl 1):S51–S58.
- Osmers R, Friede M, Liske E, Schnitker J, Freudenstein J, Henneicke-von Zepelin HH. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. *Obstet Gynecol* 2005;106:1074–1083.
- Viereck V, Gründker C, Friess SC, Frosch KH, Raddatz D, Schoppet M, Nisslein T, Emons G, Hofbauer LC. Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts. *J Bone Miner Res* 2005;20:2036–2043.
- Freudenstein J, Dasenbrock C, Nisslein T. Lack of promotion of estrogen-dependent mammary gland tumors in vivo by an isopropanolic *Cimicifuga racemosa* extract. *Cancer Res* 2002;62:3448–3452.
- Garita-Hernández M, Calzado MA, Caballero FJ, Macho A, Muñoz E, Meier B, Brattström A, Fiebich BL, Appel K. The growth inhibitory activity of the *Cimicifuga racemosa* extract Ze 450 is mediated through estrogen and progesterone receptors-independent pathways. *Planta Med* 2006;72:317–323.
- Stute P, Nisslein T, Götte M, Kamischke A, Kiesel L, Klockenbusch W. Effects of black cohosh on estrogen biosynthesis in normal breast tissue in vitro. *Maturitas* 2007; 57:382–391.
- Greene JG. A factor analytic study of climacteric symptoms. *J Psychosom Res* 1976;20:425–430.
- Utian WH, Janata JW, Kingsberg SA, Schluchter M, Hamilton JC. The Utian Quality of Life (UQOL) Scale: development and validation of an instrument to quantify quality of life through and beyond menopause. *Menopause* 2002;9:402–410.
- Palacios S, Ferrer-Barriandos J, Parrilla JJ, Castelo-Branco C, Manubens M, Alberich X, Martí A; Grupo Cervantes Health-related quality of life in the Spanish women through and beyond menopause Development and validation of the Cervantes Scale. *Med Clin (Barc)* 2004;122:205–211.
- Genazzani AR, Nicolucci A, Campagnoli C, Crosignani P, Nappi C, Serra GB, Bottiglioni E, Cianci A, De Aloysio D, Sarti CD, et al.; Progetto Donna Qualità della Vita Working Group Novo Nordisk Italia. Validation of Italian version of the Women's Health Questionnaire: assessment of quality of life of women from the general population and those attending menopause centers. *Climacteric* 2005;5:70–77.
- Chedraui P, Hidalgo L, Chavez D, Morocho N, Alvarado M, Huc A. Quality of life among postmenopausal Ecuadorian women participating in a metabolic syndrome screening program. *Maturitas* 2007;56:45–53.
- Zöllner YF, Acquadro C, Schaefer M. Literature review of instruments to assess health-related quality of life during and after menopause. *Qual Life Res* 2005;14:309–327.
- Schwarz S, Völzke H, Alte D, Schwahn C, Grabe HJ, Hoffmann W, John U, Dören M. Menopause and determinants of quality of life in women at midlife and beyond: the study of health in Pomerania (SHIP). *Menopause* 2007;14:123–134.
- Llaneza P, Iñárrrea J, González C, Alonso A, Arnott I, Ferrer-Barriandos J. Differences in health related quality of life in a sample of Spanish menopausal women with and without obesity. *Maturitas* 2007;58:387–394.
- Laferrière B, Zhu S, Clarkson JR, Yoshioka MR, Krauskopf K, Thornton JC, Pi-Sunyer FX. Race, menopause, health-related quality of life, and psychological well-being in obese women. *Obes Res* 2002;10:1270–1275.
- Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D; Million Women Study Collaboration. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. *BMJ* 2007;335:1134.
- Schilling C, Gallicchio L, Miller SR, Langenberg P, Zacur H, Flaws JA. Relation of body mass and sex steroid hormone levels to hot flushes in a sample of mid-life women. *Climacteric* 2007;10:27–37.
- Division of Mental Health and Prevention of Substance Abuse, World Health Organization. Programme on Mental Health, World Health Organization annotated bibliography of the WHOQOL. WHO; 1998, pp. 1–32.
- Gelfand MM, Moreau M, Ayotte NJ, Hilditch JR, Wong BA, Lau CY. Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: a placebo-controlled study. *Menopause* 2003;10:29–36.
- Gambacciani M, Ciapponi M, Cappagli B, Monteleone P, Benussi C, Bevilacqua G, Genazzani A. Effects of low-dose, continuous combined estradiol and norethisterone acetate on menopausal quality of life in early postmenopausal women. *Maturitas* 2003;44:157–163.
- Meeuwse IB, Samson MM, Duursma SA, Verhaar HJ. The influence of tibolone on quality of life in postmenopausal women. *Maturitas* 2002;41:35–43.
- Palacios S, Rojo IA, Cancelo MJ, Neyro JL, Castelo-Branco C. Women's perception of the efficacy of a soy extract with probiotic: the M3 study. *Gynecol Endocrinol* 2008;24: 178–183.
- Llaneza P, González C, Fernández-Iñárrrea J, Alonso A, Arnott I, Ferrer-Barriandos J. Insulin resistance and health related quality of life in post-menopausal women. *Fertil Steril*, in press.
- Kronenberg F. Hot flashes: epidemiology and physiology. *Ann NY Acad Sci* 1990;592:52–86.
- Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. *Health Qual Life Outcomes* 2005;3:47.
- Ohayon MM. Severe hot flashes are associated with chronic insomnia. *Arch Intern Med* 2006;166:1262–1268.
- Gerber LM, Sievert LL, Warren K, Pickering TG, Schwartz JE. Hot flashes are associated with increased ambulatory systolic blood pressure. *Menopause* 2007;14: 308–315.
- Gullar-Castillón P, López García E, Lozano Palacios L, Gutiérrez-Fisac JL, Banegas Banegas JR, Lafuente Urdinguio PJ, Rodríguez Artalejo F. The relationship of overweight and obesity with subjective health and use of health-care services among Spanish women. *Int J Obes Relat Metab Disord* 2002; 26:247–252.
- Jones GL, Sutton A. Quality of life in obese postmenopausal women. *Menopause Int* 2008;14:26–32.
- Nappi R, Malavasi R, Brundu B, Facchinetti F. Efficacy of *Cimicifuga racemosa* on climacteric complaints: A randomized study versus low-dose transdermal estradiol. *Gynecol Endocrinol* 2005;20:30–35.

35. Reed SD, Newton KM, LaCroix AZ, Grothaus LC, Grieco VS, Ehrlich K. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study. *Menopause* 2008;15:51–58.
36. Burdette JE, Liu J, Chen SN, Fabricant DS, Piersen CE, Barker EL, Pezzuto JM, Mesecar A, Van Breemen RB, Farnsworth NR, Bolton JL. Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. *J Agric Food Chem* 2003;51:5661–5670.
37. Huntley A, Ernst E. A systematic review of the safety of black cohosh. *Menopause* 2003;10:58–64.
38. Wutke W, Seidlová-Wutke D, Gorkow C. The Cimicifuga preparation BNO 1055 vs. Conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. *Maturitas* 2003;44:S67–S77.
39. Oktem M, Eroglu D, Karahan HB, Taskintuna N, Kuscu E, Zeyneloglu HB. Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial. *Adv Ther* 2007;24:448–461.
40. Bland J. Does complementary and alternative medicine represent only placebo therapies? *Altern Ther Health Med* 2008;14:16–18.
41. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. *PLoS Med* 2008;5:e45.
42. Whalley B, Hyland ME, Kirsch I. Consistency of the placebo effect. *J Psychosom Res* 2008;64:537–541.
43. Miller HG, Li RM. Measuring hot flashes: summary of a National Institutes of Health workshop. *Mayo Clin Proc* 2004;79:777–781.